BROSHY ERAN — SEC Form 4 filings
SEC reporting owner CIK 1256230. 8 Form 4 filings on record with FilingPulse; latest filed 2026-05-15.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-05-10 to 2026-05-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 3 filings — 133,501 shares, $2,467,520 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 29,500 shares @ $18.50 ($545,750) in Theravance Biopharma, Inc., filed 2025-11-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | Director | 5 | — | 8 legs · 133,501 sh · $2,467,520 | 7 |
| Certara, Inc. (CERT) | Director | 3 | — | — | 9 |
Form 4 filings — BROSHY ERAN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-15 | 4 | Certara, Inc. (CERT) | Option exercise (M): 15,757 @ $0 · Option exercise (M): 15,757 (derivative) @ $0 · Grant/award (A): 33,222 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | Theravance Biopharma, Inc. (TBPH) | Sale (S): 14,000 @ $20 · Sale (S): 15,501 @ $20 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-11-14 | 4/A | Theravance Biopharma, Inc. (TBPH) | Sale (S): 15,500 @ $18.50 · Sale (S): 15,500 @ $17 · Sale (S): 14,000 @ $18.50 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-11-13 | 4 | Theravance Biopharma, Inc. (TBPH) | Sale (S): 29,500 @ $18.50 · Sale (S): 15,500 @ $17 · Sale (S): 14,000 @ $18.50 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-05-22 | 4 | Certara, Inc. (CERT) | Option exercise (M): 11,928 @ $0 · Option exercise (M): 11,928 (derivative) @ $0 · Grant/award (A): 15,757 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | Certara, Inc. (CERT) | Option exercise (M): 8,663 @ $0 · Option exercise (M): 8,663 (derivative) @ $0 · Grant/award (A): 11,928 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,537 @ $0 · Grant/award (A): 23,576 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1256230 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →